GSK’s RSV Vaccine Arexvy Becomes Best Seller, Exceeding 1 Billion Euro Sales in Less Than a Year
The forecasts have been fulfilled. GSK’s respiratory syncytial virus (RSV) vaccine has become best seller in less than a year. The antigen from the British laboratory has achieved sales more than 1,000 million euros. According to the results published recently by the pharmaceutical company, sales of Arexvy (trade name for the RSV vaccine) have risen … Read more